晚期肾细胞癌-话题@MedSci

#晚期肾细胞癌#

45篇内容 | 2339人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2213710, encodeId=63b82213e1040, content=<a href='/topic/show?id=09a6598e57a' target=_blank style='color:#2F92EE;'>#晚期肾细胞癌#</a> <a href='/topic/show?id=01a536491b9' target=_blank style='color:#2F92EE;'>#卡博替尼#</a> <a href='/topic/show?id=fc2be734870' target=_blank style='color:#2F92EE;'>#纳武利尤单抗#</a> <a href='/topic/show?id=22c711634248' target=_blank style='color:#2F92EE;'>#双歧杆菌活菌产品#</a>, objectTitle=NAT MED | 肠道菌群调节剂CBM588改善晚期肾细胞癌患者接受卡博替尼和纳武利尤单抗治疗的临床疗效, objectType=article, longId=833432, objectId=0663833432e2, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240701/1719799626026_92910.jpg, objectUrl=/article/show_article.do?id=0663833432e2, replyNumber=0, likeNumber=177, createdTime=2024-07-07, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=0663833432e2, moduleTitle=NAT MED | 肠道菌群调节剂CBM588改善晚期肾细胞癌患者接受卡博替尼和纳武利尤单抗治疗的临床疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0663833432e2)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1441779, encodeId=777f1441e79b6, content=<a href='/topic/show?id=09a6598e57a' target=_blank style='color:#2F92EE;'>#晚期肾细胞癌#</a>, objectTitle=JAMA Oncol：Telaglenstat联合卡博替尼治疗转移性晚期肾细胞癌, objectType=article, longId=738547, objectId=dd49e385472d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dd49e385472d, replyNumber=0, likeNumber=148, createdTime=2022-09-09, rootId=0, userName=12498c24m70暂无昵称, userId=87304889998, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dd49e385472d, moduleTitle=JAMA Oncol：Telaglenstat联合卡博替尼治疗转移性晚期肾细胞癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dd49e385472d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1441778, encodeId=e9af1441e782f, content=<a href='/topic/show?id=09a6598e57a' target=_blank style='color:#2F92EE;'>#晚期肾细胞癌#</a>, objectTitle=Eur Urol：Pembrolizumab+Axitinib与Sunitinib治疗晚期肾细胞癌的生活质量比较, objectType=article, longId=736966, objectId=ac21e36966ab, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ac21e36966ab, replyNumber=0, likeNumber=108, createdTime=2022-08-27, rootId=0, userName=12498c24m70暂无昵称, userId=87304889998, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ac21e36966ab, moduleTitle=Eur Urol：Pembrolizumab+Axitinib与Sunitinib治疗晚期肾细胞癌的生活质量比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ac21e36966ab)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1441777, encodeId=24a31441e7708, content=<a href='/topic/show?id=09a6598e57a' target=_blank style='color:#2F92EE;'>#晚期肾细胞癌#</a>, objectTitle=Lancet Oncol：纳武单抗联合卡博替尼治疗晚期肾细胞癌的长期预后, objectType=article, longId=729046, objectId=d601e290462b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d601e290462b, replyNumber=0, likeNumber=134, createdTime=2022-06-11, rootId=0, userName=12498c24m70暂无昵称, userId=87304889998, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d601e290462b, moduleTitle=Lancet Oncol：纳武单抗联合卡博替尼治疗晚期肾细胞癌的长期预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d601e290462b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1441776, encodeId=af6d1441e76b8, content=<a href='/topic/show?id=09a6598e57a' target=_blank style='color:#2F92EE;'>#晚期肾细胞癌#</a>, objectTitle=ASCO 2022速递：晚期肾细胞癌患者的健康相关生活质量和临床结果有关吗？, objectType=article, longId=728465, objectId=896be284651f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=896be284651f, replyNumber=0, likeNumber=120, createdTime=2022-06-03, rootId=0, userName=12498c24m70暂无昵称, userId=87304889998, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=896be284651f, moduleTitle=ASCO 2022速递：晚期肾细胞癌患者的健康相关生活质量和临床结果有关吗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=896be284651f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1441775, encodeId=e32d1441e7517, content=<a href='/topic/show?id=09a6598e57a' target=_blank style='color:#2F92EE;'>#晚期肾细胞癌#</a>, objectTitle=J Immunother Cancer：Bempegaldesleukin联合纳武单抗一线治疗晚期肾细胞癌, objectType=article, longId=725499, objectId=bec0e25499db, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bec0e25499db, replyNumber=0, likeNumber=146, createdTime=2022-04-28, rootId=0, userName=12498c24m70暂无昵称, userId=87304889998, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bec0e25499db, moduleTitle=J Immunother Cancer：Bempegaldesleukin联合纳武单抗一线治疗晚期肾细胞癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bec0e25499db)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1441774, encodeId=7a811441e74ee, content=<a href='/topic/show?id=09a6598e57a' target=_blank style='color:#2F92EE;'>#晚期肾细胞癌#</a>, objectTitle=Cancer：纳武单抗联合伊匹单抗治疗晚期肾细胞癌伴有脑转移患者的安全性和有效性（CheckMate 920）, objectType=article, longId=723571, objectId=265ee235713c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=265ee235713c, replyNumber=0, likeNumber=97, createdTime=2022-04-07, rootId=0, userName=12498c24m70暂无昵称, userId=87304889998, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=265ee235713c, moduleTitle=Cancer：纳武单抗联合伊匹单抗治疗晚期肾细胞癌伴有脑转移患者的安全性和有效性（CheckMate 920）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=265ee235713c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1441773, encodeId=56241441e7396, content=<a href='/topic/show?id=09a6598e57a' target=_blank style='color:#2F92EE;'>#晚期肾细胞癌#</a>, objectTitle=J Clin Oncol：ICI联合VEGFR抑制剂治疗晚期肾细胞癌时的主要不良心血管事件风险, objectType=article, longId=300189, objectId=ad87300189e8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ad87300189e8, replyNumber=0, likeNumber=116, createdTime=2022-03-08, rootId=0, userName=12498c24m70暂无昵称, userId=87304889998, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ad87300189e8, moduleTitle=J Clin Oncol：ICI联合VEGFR抑制剂治疗晚期肾细胞癌时的主要不良心血管事件风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ad87300189e8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1441772, encodeId=340e1441e7259, content=<a href='/topic/show?id=09a6598e57a' target=_blank style='color:#2F92EE;'>#晚期肾细胞癌#</a>, objectTitle=Eur Urol Focus：Nivolumab单药治疗晚期肾细胞癌的疗效如何？, objectType=article, longId=295417, objectId=c68f29541e66, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c68f29541e66, replyNumber=0, likeNumber=138, createdTime=2022-02-12, rootId=0, userName=12498c24m70暂无昵称, userId=87304889998, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c68f29541e66, moduleTitle=Eur Urol Focus：Nivolumab单药治疗晚期肾细胞癌的疗效如何？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c68f29541e66)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1441771, encodeId=037e1441e710c, content=<a href='/topic/show?id=09a6598e57a' target=_blank style='color:#2F92EE;'>#晚期肾细胞癌#</a>, objectTitle=Clin Cancer Res：晚期肾细胞癌患者免疫治疗停药后的无治疗生存期（TFS）：Check- Mate 214研究, objectType=article, longId=221415, objectId=e7312214158c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e7312214158c, replyNumber=0, likeNumber=103, createdTime=2021-12-03, rootId=0, userName=12498c24m70暂无昵称, userId=87304889998, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e7312214158c, moduleTitle=Clin Cancer Res：晚期肾细胞癌患者免疫治疗停药后的无治疗生存期（TFS）：Check- Mate 214研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e7312214158c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1441770, encodeId=0d951441e70db, content=<a href='/topic/show?id=09a6598e57a' target=_blank style='color:#2F92EE;'>#晚期肾细胞癌#</a>, objectTitle=Clin Cancer Res：中性粒细胞/淋巴细胞比值(NLR)与avelumab联合阿昔替尼或舒尼替尼治疗晚期肾细胞癌（RCC）疗效的关系: 来自JAVELIN Renal 101研究, objectType=article, longId=221216, objectId=48642212160d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=48642212160d, replyNumber=0, likeNumber=123, createdTime=2021-11-30, rootId=0, userName=12498c24m70暂无昵称, userId=87304889998, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=48642212160d, moduleTitle=Clin Cancer Res：中性粒细胞/淋巴细胞比值(NLR)与avelumab联合阿昔替尼或舒尼替尼治疗晚期肾细胞癌（RCC）疗效的关系: 来自JAVELIN Renal 101研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=48642212160d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1441769, encodeId=e3e91441e69b9, content=<a href='/topic/show?id=09a6598e57a' target=_blank style='color:#2F92EE;'>#晚期肾细胞癌#</a>, objectTitle=Clin Cancer Res：晚期肾细胞癌免疫+靶向治疗后的无治疗生存期, objectType=article, longId=220642, objectId=32a82206422f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=32a82206422f, replyNumber=0, likeNumber=193, createdTime=2021-11-21, rootId=0, userName=12498c24m70暂无昵称, userId=87304889998, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=32a82206422f, moduleTitle=Clin Cancer Res：晚期肾细胞癌免疫+靶向治疗后的无治疗生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=32a82206422f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1441768, encodeId=85981441e68a4, content=<a href='/topic/show?id=09a6598e57a' target=_blank style='color:#2F92EE;'>#晚期肾细胞癌#</a>, objectTitle=Clin Cancer Res：nivolumab + ipilimumab对比舒尼替尼治疗晚期肾细胞癌（aRCC）患者后的无治疗生存时间（TFS）对比：来自Check- Mate 214研究结果, objectType=article, longId=220254, objectId=cfa922025489, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cfa922025489, replyNumber=0, likeNumber=107, createdTime=2021-11-14, rootId=0, userName=12498c24m70暂无昵称, userId=87304889998, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cfa922025489, moduleTitle=Clin Cancer Res：nivolumab + ipilimumab对比舒尼替尼治疗晚期肾细胞癌（aRCC）患者后的无治疗生存时间（TFS）对比：来自Check- Mate 214研究结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cfa922025489)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1441767, encodeId=cdf91441e6734, content=<a href='/topic/show?id=09a6598e57a' target=_blank style='color:#2F92EE;'>#晚期肾细胞癌#</a>, objectTitle=J Clin Oncol：卡博替尼与阿特珠单抗的联合方案在晚期肾细胞癌中初露锋芒！, objectType=article, longId=216873, objectId=09412168e302, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=09412168e302, replyNumber=0, likeNumber=87, createdTime=2021-09-11, rootId=0, userName=12498c24m70暂无昵称, userId=87304889998, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=09412168e302, moduleTitle=J Clin Oncol：卡博替尼与阿特珠单抗的联合方案在晚期肾细胞癌中初露锋芒！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=09412168e302)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1441766, encodeId=551e1441e6668, content=<a href='/topic/show?id=09a6598e57a' target=_blank style='color:#2F92EE;'>#晚期肾细胞癌#</a>, objectTitle=Eur Urol Oncol：晚期肾细胞癌患者接受一线Pembrolizumab加Axitinib治疗时出现的肝脏毒性的特征和管理, objectType=article, longId=214935, objectId=823a21493535, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=823a21493535, replyNumber=0, likeNumber=67, createdTime=2021-07-29, rootId=0, userName=12498c24m70暂无昵称, userId=87304889998, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=823a21493535, moduleTitle=Eur Urol Oncol：晚期肾细胞癌患者接受一线Pembrolizumab加Axitinib治疗时出现的肝脏毒性的特征和管理, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=823a21493535)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1441765, encodeId=557a1441e65b1, content=<a href='/topic/show?id=09a6598e57a' target=_blank style='color:#2F92EE;'>#晚期肾细胞癌#</a>, objectTitle=NEJM ：乐伐替尼-派姆单抗治疗晚期肾细胞癌效果优于舒尼替尼, objectType=article, longId=209719, objectId=aeac209e1906, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aeac209e1906, replyNumber=0, likeNumber=150, createdTime=2021-04-10, rootId=0, userName=柳叶一刀, userId=778d36, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aeac209e1906, moduleTitle=NEJM ：乐伐替尼-派姆单抗治疗晚期肾细胞癌效果优于舒尼替尼, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aeac209e1906)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1441764, encodeId=6a791441e6432, content=<a href='/topic/show?id=09a6598e57a' target=_blank style='color:#2F92EE;'>#晚期肾细胞癌#</a>, objectTitle=Eur Urol：高风险局部和局部晚期肾细胞癌手术切除后的疾病复发、早期进展和总生存率预测 , objectType=article, longId=208759, objectId=4547208e591f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4547208e591f, replyNumber=0, likeNumber=144, createdTime=2021-03-22, rootId=0, userName=12498c24m70暂无昵称, userId=87304889998, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4547208e591f, moduleTitle=Eur Urol：高风险局部和局部晚期肾细胞癌手术切除后的疾病复发、早期进展和总生存率预测 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4547208e591f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1441763, encodeId=cf4d1441e6339, content=<a href='/topic/show?id=09a6598e57a' target=_blank style='color:#2F92EE;'>#晚期肾细胞癌#</a>, objectTitle=NEJM：Nivolumab联合Cabozantinib治疗晚期肾细胞癌, objectType=article, longId=207911, objectId=9b3720e91188, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9b3720e91188, replyNumber=0, likeNumber=96, createdTime=2021-03-07, rootId=0, userName=12498c24m70暂无昵称, userId=87304889998, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9b3720e91188, moduleTitle=NEJM：Nivolumab联合Cabozantinib治疗晚期肾细胞癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9b3720e91188)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1441762, encodeId=89851441e6205, content=<a href='/topic/show?id=09a6598e57a' target=_blank style='color:#2F92EE;'>#晚期肾细胞癌#</a>, objectTitle=Opdivo（nivolumab）联合Cabometyx（cabozantinib）一线治疗晚期肾细胞癌，CHMP持积极意见, objectType=article, longId=207706, objectId=989b20e706d8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=989b20e706d8, replyNumber=0, likeNumber=75, createdTime=2021-03-01, rootId=0, userName=12498c24m70暂无昵称, userId=87304889998, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=989b20e706d8, moduleTitle=Opdivo（nivolumab）联合Cabometyx（cabozantinib）一线治疗晚期肾细胞癌，CHMP持积极意见, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=989b20e706d8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1441761, encodeId=5ea61441e61bc, content=<a href='/topic/show?id=09a6598e57a' target=_blank style='color:#2F92EE;'>#晚期肾细胞癌#</a>, objectTitle=ASCO GU 2021: Nivolumab联合Cabozantinib与舒尼替尼在晚期肾细胞癌中效果对比（CheckMate 9ER研究）, objectType=article, longId=207196, objectId=04c620e196a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=04c620e196a7, replyNumber=0, likeNumber=112, createdTime=2021-02-18, rootId=0, userName=12498c24m70暂无昵称, userId=87304889998, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=04c620e196a7, moduleTitle=ASCO GU 2021: Nivolumab联合Cabozantinib与舒尼替尼在晚期肾细胞癌中效果对比（CheckMate 9ER研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=04c620e196a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

晚期肾细胞癌

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#晚期肾细胞癌# #卡博替尼# #纳武利尤单抗# #双歧杆菌活菌产品#

NAT MED | 肠道菌群调节剂CBM588改善晚期肾细胞癌患者接受卡博替尼和纳武利尤单抗治疗的临床疗效

2024-07-07发表于上海

12498c24m70暂无昵称 (审核中...)

前往app查看评论内容

#晚期肾细胞癌#

JAMA Oncol：Telaglenstat联合卡博替尼治疗转移性晚期肾细胞癌

2022-09-09

12498c24m70暂无昵称 (审核中...)

前往app查看评论内容

#晚期肾细胞癌#

Eur Urol：Pembrolizumab+Axitinib与Sunitinib治疗晚期肾细胞癌的生活质量比较

2022-08-27

12498c24m70暂无昵称 (审核中...)

前往app查看评论内容

#晚期肾细胞癌#

Lancet Oncol：纳武单抗联合卡博替尼治疗晚期肾细胞癌的长期预后

2022-06-11

12498c24m70暂无昵称 (审核中...)

前往app查看评论内容

#晚期肾细胞癌#

ASCO 2022速递：晚期肾细胞癌患者的健康相关生活质量和临床结果有关吗？

2022-06-03

12498c24m70暂无昵称 (审核中...)

前往app查看评论内容

#晚期肾细胞癌#

J Immunother Cancer：Bempegaldesleukin联合纳武单抗一线治疗晚期肾细胞癌

2022-04-28

12498c24m70暂无昵称 (审核中...)

前往app查看评论内容

#晚期肾细胞癌#

Cancer：纳武单抗联合伊匹单抗治疗晚期肾细胞癌伴有脑转移患者的安全性和有效性（CheckMate 920）

2022-04-07

12498c24m70暂无昵称 (审核中...)

前往app查看评论内容

#晚期肾细胞癌#

J Clin Oncol：ICI联合VEGFR抑制剂治疗晚期肾细胞癌时的主要不良心血管事件风险

2022-03-08

12498c24m70暂无昵称 (审核中...)

前往app查看评论内容

#晚期肾细胞癌#

Eur Urol Focus：Nivolumab单药治疗晚期肾细胞癌的疗效如何？

2022-02-12

12498c24m70暂无昵称 (审核中...)

前往app查看评论内容

#晚期肾细胞癌#

Clin Cancer Res：晚期肾细胞癌患者免疫治疗停药后的无治疗生存期（TFS）：Check- Mate 214研究

2021-12-03

12498c24m70暂无昵称 (审核中...)

前往app查看评论内容

#晚期肾细胞癌#

Clin Cancer Res：中性粒细胞/淋巴细胞比值(NLR)与avelumab联合阿昔替尼或舒尼替尼治疗晚期肾细胞癌（RCC）疗效的关系: 来自JAVELIN Renal 101研究

2021-11-30

12498c24m70暂无昵称 (审核中...)

前往app查看评论内容

#晚期肾细胞癌#

Clin Cancer Res：晚期肾细胞癌免疫+靶向治疗后的无治疗生存期

2021-11-21

12498c24m70暂无昵称 (审核中...)

前往app查看评论内容

#晚期肾细胞癌#

Clin Cancer Res：nivolumab + ipilimumab对比舒尼替尼治疗晚期肾细胞癌（aRCC）患者后的无治疗生存时间（TFS）对比：来自Check- Mate 214研究结果

2021-11-14

12498c24m70暂无昵称 (审核中...)

前往app查看评论内容

#晚期肾细胞癌#

J Clin Oncol：卡博替尼与阿特珠单抗的联合方案在晚期肾细胞癌中初露锋芒！

2021-09-11

12498c24m70暂无昵称 (审核中...)

前往app查看评论内容

#晚期肾细胞癌#

Eur Urol Oncol：晚期肾细胞癌患者接受一线Pembrolizumab加Axitinib治疗时出现的肝脏毒性的特征和管理

2021-07-29

柳叶一刀 (审核中...)

前往app查看评论内容

#晚期肾细胞癌#

NEJM ：乐伐替尼-派姆单抗治疗晚期肾细胞癌效果优于舒尼替尼

2021-04-10

12498c24m70暂无昵称 (审核中...)

前往app查看评论内容

#晚期肾细胞癌#

Eur Urol：高风险局部和局部晚期肾细胞癌手术切除后的疾病复发、早期进展和总生存率预测

2021-03-22

12498c24m70暂无昵称 (审核中...)

前往app查看评论内容

#晚期肾细胞癌#

NEJM：Nivolumab联合Cabozantinib治疗晚期肾细胞癌

2021-03-07

12498c24m70暂无昵称 (审核中...)

前往app查看评论内容

#晚期肾细胞癌#

Opdivo（nivolumab）联合Cabometyx（cabozantinib）一线治疗晚期肾细胞癌，CHMP持积极意见

2021-03-01

12498c24m70暂无昵称 (审核中...)

前往app查看评论内容

#晚期肾细胞癌#

ASCO GU 2021: Nivolumab联合Cabozantinib与舒尼替尼在晚期肾细胞癌中效果对比（CheckMate 9ER研究）

2021-02-18

科室
- - 订阅+
  - 更多科室
工具
服务